The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interleukin 1β Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency
Open accessAbstract
IL10 receptor (IL10R)-deficient mice develop spontaneous colitis and similarly, patients with loss-of-function mutations in IL10R develop severe infant-onset inflammatory bowel disease (IBD). Loss of IL10R signaling in mouse and human macrophages is associated with increased production of interleukin 1 beta (IL1B). We demonstrated that innate immune production of IL1B mediates colitis in IL10R-deficient mice. Transfer of Il1r1−/− CD4+ T cells into Rag1−/−/Il10rb−/− mice reduced the severity of their colitis (compared to mice that received CD4+ T cells that express IL1R), accompanied by decreased production of interferon gamma, tumor necrosis factor, and IL17A. In macrophages from mice without disruption of IL10R signaling or from healthy humans (controls), incubation with IL10 reduced canonical activation of the inflammasome and production of IL1B through transcriptional and post-translational regulation of NLRP3. Lipopolysaccharide (LPS) and adenosine triphosphate stimulation of macrophages from Il10rb−/− mice or IL10R-deficient patients increased production of IL1B. Moreover, in human IL10R-deficient macrophages, LPS stimulation alone increased IL1B secretion via non-canonical, caspase 8-dependent activation of the inflammasome. We treated 2 IL10-receptor deficient patients with severe and treatment-refractory infant-onset IBD with the IL1 receptor antagonist anakinra. Both patients had marked clinical, endoscopic, and histologic responses after 4–7 weeks. This treatment served as successful bridge to allogeneic hematopoietic stem cell transplantation in 1 patient. Our findings indicate that loss of IL10 signaling leads to intestinal inflammation, at least in part, through increased production of IL1 by innate immune cells, leading to activation of CD4+ T cells. Agents that block IL1 signaling might be used to treat patients with IBD resulting from IL10R deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945
Cited by
Toll-like Receptors and the Control of Immunity
Fitzgerald, K. A., & Kagan, J. C. (2020) · Cell · doi:10.1016/j.cell.2020.02.041 · Cited by 2,168
Pathway paradigms revealed from the genetics of inflammatory bowel disease
Graham, D. B., & Xavier, R. J. (2020) · Nature · doi:10.1038/s41586-020-2025-2 · Cited by 771
Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Friedrich, M., Pohin, M., & Powrie, F. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.017 · Cited by 750
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Neurath, M. F. (2019) · Nature Immunology · doi:10.1038/s41590-019-0415-0 · Cited by 701
NLRP3 Inflammasome and Inflammatory Bowel Disease
Zhen, Y., & Zhang, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00276 · Cited by 649
Metadata
- Authors
- Shouval, D. S., Biswas, A., Kang, Y. H., Griffith, A. E., Konnikova, L., Mascanfroni, I. D., Redhu, N. S., Frei, S. M., Field, M., Doty, A. L., Goldsmith, J. D., Bhan, A. K., Loizides, A., Weiss, B., Yerushalmi, B., Yanagi, T., Lui, X., Quintana, F. J., Muise, A. M., Klein, C., Horwitz, B. H., Glover, S. C., Bousvaros, A., & Snapper, S. B.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 151
- Issue
- 6
- Pages
- 1100-1104
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2537725318
- Cited by
- 182
- References
- 1
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.